在帕金森病中,阿迪波涅丁与脂质之间的关联
Mayu Sugata1, Hiroshi Kataoka1, Kazuma Sugie1
1Department of Neurology, Nara Medical University, Nara, Japan.
Clinical neurology and neurosurgery
|April 28, 2025
概括
在接受治疗的帕金森病 (PD) 患者中,相比于 de-novo PD 或 PSP,阿迪波涅克 (APN) 水平更高. APN可以将PD与其他神经退行性疾病 (如MSA-P和PSP) 区分开来.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 脂质代谢 脂质代谢 是一种
- 发现生物标志物的发现.
背景情况:
- 帕金森病 (PD) 越来越多地与脂质有关,在Lewy体中发现的脂质和在化α-synuclein中发现的脂素 (APN).
- 在Lewy体中观察到高分子量氨酸 (APN),这表明它可能在PD病变发生过程中发挥作用.
研究的目的:
- 调查阿迪波涅克丁 (APN) 水平与神经退行性疾病之间的关联.
- 在这些条件下探索APN与体重之间的关系.
主要方法:
- 采集了静脉血液样本,以测量葡萄糖,脂质 (包括HDL-C,LDL-C) 和脂肪素 (APN).
- 用了包括ANCOVA在内的统计分析来比较不同患者组的APN水平,并评估相关性.
主要成果:
- 经过治疗的PD患者的APN水平明显高于未经治疗的PD,PSP或MSA-P患者.
- 在PD患者中,APN水平与HDL胆固醇 (HDL-C) 有正相关,但在MSA-P或PSP患者中没有.
- 与治疗PD患者相比,de-novoPD患者的身体质量指数 (BMI) 略高.
结论:
- 皮菌素 (APN) 可能在脂质中发挥作用,特别是在治疗PD.
- APN和HDL-C之间的相关性可以作为一个潜在的生物标志物来区分PD与MSA-P和PSP.
更多相关视频
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
9.2K
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
5.8K
相关概念视频
Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
Parkinson's Disease: Overview
308
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
308
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Lysosomal Hydrolases
3.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K
Lipid Digestion
88.9K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
88.9K
